Cancers in distant organs alter liver function

Cancers often release molecules into the bloodstream that pathologically alter the liver, shifting it to an inflammatory state, causing fat buildup and impairing its normal detoxifying functions, according to a study from investigators at Weill Cornell Medicine. This discovery illuminates one of cancer’s more insidious survival mechanisms and suggests the possibility of new tests and drugs for detecting and reversing this process.

In the study, published May 24 in Nature, the researchers found that a wide variety of tumor types growing outside the liver remotely reprogram the liver to a state resembling fatty liver disease via secretion of extracellular vesicles and particles (EVPs) containing fatty acids. The scientists found evidence of this process in animal models of cancer and in the livers of human cancer patients.

“Our findings show that tumors can lead to significant systemic complications including liver disease, but also suggest that these complications can be addressed with future treatments,” said study co-senior author Dr. David Lyden, the Stavros S. Niarchos Professor in Pediatric Cardiology and a professor of pediatrics and of cell and developmental biology at Weill Cornell Medicine.

For the past two decades, Dr. Lyden, who is also a member of the Gale and Ira Drukier Institute for Children’s Health and the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, and his research group have been studying the systemic effects of cancers. These effects reflect specific strategies cancers use to secure their survival and speed their progression. In their work published in 2015, for example, the team discovered that pancreatic cancers secrete molecules encapsulated in extracellular vesicles, that travel through the bloodstream, are taken up by the liver, and prepare the organ to support the outgrowth of new, metastatic tumors.

In the new study, the researchers uncovered a different set of liver changes caused by distant cancer cells which they observed in animal models of bone, skin and breast cancer that metastasize to other organs but not to the liver. The study’s key finding is that these tumors induce accumulation of fat molecules in liver cells, consequently reprogramming the liver in a way that resembles the obesity- and alcohol-related condition known as fatty liver disease.

The team also observed that reprogrammed livers have high levels of inflammation, marked by elevated level of tumor necrosis factor-α (TNF-α), and low levels of drug-metabolizing enzymes called cytochrome P450, which break down potentially toxic molecules, including many drug molecules. The observed reduction in cytochrome P450 levels could explain why cancer patients often become less tolerant of chemotherapy and other drugs as their illness progresses.

The researchers traced this liver reprogramming to EVPs that are released by the distant tumors and carry fatty acids, especially palmitic acid. When taken up by liver-resident immune cells called Kupffer cells, the fatty acid cargo triggers the production TNF-α, which consequently drives fatty liver formation.

Although the researchers principally used animal models of cancers in the study, they observed similar changes in the livers of newly diagnosed pancreatic cancer patients who later developed non-liver metastases.

“One of our more striking observations was that this EVP-induced fatty liver condition did not co-occur with liver metastases, suggesting that causing fatty liver and preparing the liver for metastasis are distinct strategies that cancers use to manipulate liver function,” said co-first author Dr. Gang Wang, a postdoctoral associate in the Lyden laboratory. Dr. Jianlong Li, a scientific collaborator in the Lyden laboratory, is also a co-first author of the study.

The scientists suspect that the fatty liver condition benefits cancers in part by turning the liver into a lipid-based source of energy to fuel cancer growth.

“We see in liver cells not only an abnormal accumulation of fat but also a shift away from the normal processing of lipids, so that the lipids that are being produced are more advantageous to the cancer,” said co-senior author Dr. Robert Schwartz, associate professor of medicine in the Division of Gastroenterology and Hepatology and a member of the Meyer Cancer Center at Weill Cornell Medicine and a hepatologist at NewYork-Presbyterian/Weill Cornell Medical Center.

That may not be the only benefit that cancers derive from this liver alteration. “There are also crucial molecules involved in immune cell function, but their production is altered in these fatty livers, hinting that this condition may also weakens anti-tumor immunity,” said co-senior author Dr. Haiying Zhang, assistant professor of cell and developmental biology in pediatrics at Weill Cornell Medicine.

The researchers were able to mitigate these systemic effects of tumors on the livers by implementing strategies such as blocking tumor-EVP release, inhibiting the packaging of palmitic acid into tumor EVPs, suppressing TNF-α activity, or eliminating Kupffer cells in the experimental animal models. The researchers are further investigating the potential of implementing these strategies in human patients to block these remote effects of tumors on the liver, and exploring the possibility of utilizing the detection of palmitic acid in tumor EVPs circulating in the blood as a potential warning sign of advanced cancer.

Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. For this information, see profiles for Dr. David Lyden and Dr. Robert Schwartz.